Thus, in our study, it appears testosterone levels are countered by high levels of SHBG, particularly in women using OCPs with anti-androgenic progestogens, thereby reducing free testosterone to an extent that the androgen-driven anticipated increase in insulin resistance was mitigated in that group relative to the androgenic pill users. This evidence concerns the gene SHBG and Insulin resistance.